Clinical trials: Chikungunya Fever
Chikungunya Virus
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], aluminum hydroxide adjuvanted).
- Trial name
- CHIKV VLP (NCT05065983)
- Testing
- CHIKV VLP, adjuvanted
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya Virus Infection
Phase I Trial of Measles Vectored Chikungungya Vaccine
This study is a randomized, double-blinded, Phase 1, placebo- controlled, and dose comparison trial to evaluate the safety, immunogenicity and schedule of MV-CHIK. Two dosage levels and 3 immunization schedules will be evaluated.
- Trial name
- NCT03028441
- Testing
- VRC-CHKVLP059-00-VP
- Where
- 3 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus Infection
Phase 1 Study of SAR440894 vs Placebo
A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at multiple sites.
- Trial name
- NCT04441905
- Testing
- SAR440894
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus Infection
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
This is an observational, non-interventional, test-negative case-control (TNCC) study to estimate the vaccine effectiveness of VLA1553 against Chikungunya virus in a real-world setting.
- Trial name
- NCT07347002
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Chikungunya Virus Infection
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
- Trial name
- NCT04838444
- Testing
- VLA1553
- Where
- 10 sites in United States
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Zika
Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale
Mosquito-borne diseases cause suffering for hundreds of millions of people and claim more than 700,000 lives yearly. Diseases such as dengue, Zika, and chikungunya cause symptoms similar to malaria and are endemic in many parts…
- Conditions
- Dengue, Zika, Chikungunya
- Trial name
- NCT06595745
- Testing
- Wolbachia induced incompatible mating, Standard traditional chemical mosquito control
- Where
- Mexico
- Volunteers
- 15,243 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Chikungunya Virus Infection
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate…
- Trial name
- NCT06007183
- Testing
- CHIKV VLP vaccine booster
- Where
- 24 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Viral Vaccines, Chikungunya Fever
Chikungunya Virus Vaccine Trial in Healthy Adults
Background: Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death.
- Conditions
- Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
- Trial name
- NCT01489358
- Testing
- VRC-CHKVLP059-00-VP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy participants.
- Trial name
- NCT03325075
- Testing
- VAL-181388
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Zika Virus, Pregnancy Related
ZIKAlliance Pregnant Women Cohort
The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations.
- Trial name
- ZIKAlliancePW (NCT03188731)
- Where
- 14 sites in Bolivia, Brazil and 5 more
- Volunteers
- 3,852 people, healthy volunteers welcome
- Sponsor
- University of Heidelberg Medical Center
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Chikungunya, Arthritis
Chikungunya Arthritis in the Americas
Chikungunya is a mosquito-borne viral illness that leads to chronic joint pain in approximately one half of patients. The mechanisms leading to long term arthritis in humans has not been well established.
- Trial name
- NCT02463968
- Testing
- Venipuncture for blood draw, Arthrocentesis for synovial fluid draw
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- George Washington University
Chikungunya, Zika
Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.
Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as…
- Trial name
- NCT04440774
- Testing
- CHIK low dose, CHIK mid dose, CHIK high dose
- Where
- Mexico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Oxford